Results 241 to 250 of about 278,076 (329)
TriCON: A Carbon‐Based Triple‐Modal Nanoplatform for Pancreatic Cancer Therapy
We developed TriCON, a triple‐modality nanotherapeutic platform, to treat pancreatic ductal adenocarcinoma (PDAC) by synergizing gene editing, chemotherapy, and immunotherapy. TriCON utilizes CRISPR/Cas9 to target the poliovirus receptor (PVR), combined with nano‐encapsulated doxorubicin and checkpoint blockade. This approach achieved significant tumor
Xinyu Peng +9 more
wiley +1 more source
Therapeutic applications of CRISPR-Cas9 gene editing. [PDF]
Bharti A, Mudge J.
europepmc +1 more source
This study demonstrates that dual UCP2/IL‐17 blockade reprograms T‐cell metabolism to overcome PDAC immunosuppression. Genipin‐mediated UCP2 inhibition enhances CD8⁺ T‐cell IFN‐γ via IL‐12R/STAT4/mTOR signaling and mitochondrial OXPHOS. Combined IL‐17 depletion amplifies Tc1/Th1 responses, reduces MDSCs, and prolongs survival in PDAC models ...
Chuan‐Teng Liu +11 more
wiley +1 more source
Advancing cellulose degradation through synthetic biology: engineered pathways and microbial systems for sustainable biomass conversion. [PDF]
Liu X, Quan J, Li Y, Wang X, Zhao J.
europepmc +1 more source
CRISPR-Cas9-induced double-strand breaks disrupt maintenance of epigenetic information
Mengge Wang +3 more
openalex +1 more source
Extracellular vesicles (EVs) released from TGF‐β‐activated CAFs are enriched with ECM proteins such as TSG6 and THBS1, which facilitate their binding to recipient cell membranes. This EV–cell interaction promotes the clustering of CD44 and TGF‐β receptors on the target cell surface, thereby potentiating TGF‐β signaling activity. This study highlights a
Chao Li +7 more
wiley +1 more source
Synthetic essentiality of isoprenylcysteine carboxylmethyltransferase in PTEN deficient triple negative breast cancer. [PDF]
Park BS +6 more
europepmc +1 more source

